IMRX
Immuneering Corp
NASDAQ · Healthcare · Biotechnology · US
$4.48
+0.45%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$4.48
From 52W high−51.62%
Volume1.08M
Market cap$289.84M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$4.48
From 52W high
−51.62%
Volume
1.08M
Market cap
$289.84M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.3x
P/E (TTM)
—
RSI (14)
40.2
MomentumView details →
1D Return
+0.45%
YTD Return
−32.37%
SummaryUpdated Jun 1, 2026
Immuneering Corporation (NASDAQ:IMRX) is a clinical-stage biopharmaceutical company founded in 2008 and headquartered in Cambridge, Massachusetts. Originally a subsidiary of Teva Pharmaceutical Industries, the company went public in July 2021. Immuneering focuses on developing novel cancer treatments that target specific cellular pathways involved in tumor growth, particularly the RAS/RAF/MEK pathway which is commonly mutated in various cancers.
Similar companies
Latest newsMore news →
Immuneering Corporation announced it will present a poster on atebimetinib's dual mechanism for extended survival at the AACR Conference on Pancreatic Cancer taking place September 25-28, 2026, in San Diego.10d agoImmuneering Corporation reported its financial results for the second quarter ended June 30, 2026, ending with $182.7 million in cash, cash equivalents and marketable securities with anticipated runway into 2029.46d agoImmuneering Corporation appointed Andrew Gengos as Chief Financial Officer, effective July 16.97d ago